 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...1213141516171819202122...4142» |
- Ibrance (palbociclib) / Pfizer, giredestrant (GDC-9545) / Roche
Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study (Stars at Night 1/2) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1524;
P2
Conclusions The study will proceed to the primary analysis. We expect to see encouraging results based on the favorable interim analysis data that demonstrated the superior activity of giredestrant, an oral selective estrogen receptor antagonist and degrader, compared with anastrozole.
- Ibrance (palbociclib) / Pfizer
Identifying a metabolite signature that correlates with tumor proliferation in early-stage breast cancer patients treated with CDK4/6 inhibitors from matched plasma and serum samples (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1374;
P2
In addition, a BoR model based on select metabolites could precisely stratify palbo-response in a blinded dataset. A larger independent validation cohort is ongoing.
- tamoxifen / Generic mfg.
Breast cancer survivors vulvo-vaginal atrophy symptoms: Morphological aspects unveiled (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1222;
Were included 62 women, 50 BCSA (18 - tamoxifen and 32 - anastrozole) and 12 control group. Symptoms of VVA do not correlate with tissue modifications as expected, however a trend of enhance of papillomatosis and subepithelial vascularization was observed, and they were predominant in BCSA compared to controls.
- tamoxifen / Generic mfg.
Impact of endocrine therapy (ET) noncompliance following intra-operative radiation therapy (IORT) in treatment of early-stage breast cancer patients (pts) enrolled in the ExBRT trial (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1036;
Early-stage ER+ breast cancer pts compliant with a subsequent course of ET in this study experienced a lower IBTR rate, improving the collective outcome of their multidisciplinary treatment. These preliminary ExBRT trial results demonstrate that IBTR rates are improved with ET compliance.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_627;
The outcome of this study demonstrated that patients with mutations on known ESR1 hotspots (E380Q, L536H, Y537N/C/S and D538G) develop clinical resistance to endocrine therapy. Evaluation of these ESR1 hotspots mutations by ctDNA could be reliably used to monitor the response to endocrine therapy and predict the prognosis for MBC patients.
- Verzenio (abemaciclib) / Eli Lilly
Abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitor in participants with HR+, HER2- breast cancer - A pooled analysis of the endocrine therapy-naïve participants with measurable disease in MONARCH 2 and MONARCH 3 (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_579;
P3
Primary analysis of confirmed ORR in M2 and M3 EN participants with measurable disease compares favorably with previously reported ORR for fulvestrant monotherapy (FALCON study: 46% unconfirmed; FIRST study: 36% unconfirmed) or NSAI (PALOMA-2 study: 44.8% confirmed; MONALEESA-2: 34% unconfirmed) in participants with a similar disease state. The safety profile is similar to that reported in the primary M2 and M3 main studies.
- tamoxifen / Generic mfg.
Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_554;
Similarly, an exploratory analysis from the ATAC trial found that in post-menopausal women with early-stage BC, overall recurrence rates were lower in patients randomized to anastrozole versus tamoxifen but in women with body mass index (BMI) > 30, there was no significant difference in disease recurrence between anastrozole and tamoxifen...Overall, 53% were on letrozole, 42% on anastrozole and 5.5% on exemestane...This discrepancy could be due to other differences in disease characteristics that make complete aromatase inhibition more important in the adjuvant setting when disease burden is the lowest. Additional larger studies are needed to confirm this finding.
- || tamoxifen / Generic mfg., fulvestrant / Generic mfg.
Biomarker, Clinical, Journal: IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. (Pubmed Central) - Oct 25, 2021
P2
We found a direct relationship between post-treatment estradiol levels and the magnitude of the Ki67 decrease in tumors. These data suggest IHC-based Ki67 may be an appropriate biomarker for tamoxifen response in premenopausal breast cancer patients, but anti-proliferative effect size depends on estradiol levels.
- || Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal: A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole (Pubmed Central) - Oct 22, 2021
These data suggest IHC-based Ki67 may be an appropriate biomarker for tamoxifen response in premenopausal breast cancer patients, but anti-proliferative effect size depends on estradiol levels. CDK4/6 inhibitors, in combination with anastrozole, will play a pivotal role in the initial approach to elderly patients with HR+ late recurrence as a chemotherapy- free strategy.
- | anastrozole / Generic mfg.
Journal: Testicular testosterone and estradiol concentrations and aromatase expression in men with nonobstructive azoospermia. (Pubmed Central) - Oct 22, 2021
A close association between the expression of aromatase in Leydig cells and ITT/ITE2 was shown. Leydig cell aromatase is a factor that is independently correlated with spermatogenesis, and aromatase inhibitors may open a therapeutic window by increasing the ITT/ITE2 in selected patients.
- || letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. (Pubmed Central) - Oct 22, 2021
P3
Compared with KM methods, competing risk analyses result in lower estimates of DFS and DRFS events and similar or modestly lower absolute benefit from experimental endocrine therapy. Over a long time horizon, competing risk methods may be preferable to KM methods when estimating future risk of recurrence in early-stage hormone-sensitive breast cancer.
- || anastrozole / Generic mfg.
Clinical, Journal: Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women? (Pubmed Central) - Oct 20, 2021
Over a long time horizon, competing risk methods may be preferable to KM methods when estimating future risk of recurrence in early-stage hormone-sensitive breast cancer. Our preliminary data suggested that the palliative use of anastrozole may be a suitable therapy for the proper management of early stages endometrial cancer in elderly women not suitable for surgical treatment with good compliance and tolerance.
- | NN1213 / Novo Nordisk
Enrollment closed, Enrollment change, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Oct 18, 2021
P2, N=19, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Our preliminary data suggested that the palliative use of anastrozole may be a suitable therapy for the proper management of early stages endometrial cancer in elderly women not suitable for surgical treatment with good compliance and tolerance. Recruiting --> Active, not recruiting | N=29 --> 19
- lisinopril / Generic mfg.
[VIRTUAL] Primary Membranous Nephropathy Flare After COVID-19 Vaccination () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2435;
We present a patient with MN and metastatic breast cancer who developed nephrotic syndrome after receiving her second mRNA-1273 COVID-19 vaccine with positive PLA2R Ab by ELISA suggesting MN flare...She was diagnosed with metastatic breast cancer and started anastrazole transiently...She was treated with lisinopril and furosemide followed by rituximab in May 2021...Our case of primary MN flare after COVID-19 vaccine adds support to a potential association between SARS-CoV-2 antigens and loss of tolerance to the PLA2R antigen. Close follow-up of patients with primary MN and other glomerular diseases after COVID-19 vaccination is warranted.
- || tamoxifen / Generic mfg.
Clinical, Journal: Switching of Hormone Therapies in Breast Cancer Women. (Pubmed Central) - Oct 16, 2021
Among the reasons for changing therapy, the most common was disease progression, which includes cancer recurrence, metastasis or increased tumor. Side effects were second; furthermore, age and comorbidities are risk factors for side effects.
- || tamoxifen / Generic mfg.
Review, Journal: Review of the Literature on Ocular Complications Associated With Aromatase Inhibitor Use. (Pubmed Central) - Oct 15, 2021
Aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane, are commonly used as adjuvant endocrine therapy in hormone-receptive breast cancer in postmenopausal women...The ocular side effects of tamoxifen use are well documented and were not included...Although these are likely rare side effects, we recommend a high level of clinical suspicion when assessing patients with visual symptoms and on AIs. Larger prospective studies are necessary to further investigate these complications.
- || xentuzumab (BI-836845) / Boehringer Ingelheim
Enrollment closed, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - Oct 14, 2021
P1, N=133, Active, not recruiting, Sponsor: Boehringer Ingelheim
Larger prospective studies are necessary to further investigate these complications. Recruiting --> Active, not recruiting
- | Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Combination therapy, Metastases: Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (clinicaltrials.gov) - Oct 14, 2021
P1, N=44, Recruiting, Sponsor: Medical College of Wisconsin
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- anastrozole / Generic mfg.
[VIRTUAL] CLOT OR NOT? AN UNUSUAL CTEPH MIMIC () - Oct 13, 2021 - Abstract #CHEST2021CHEST_2276;
CASE PRESENTATION: A 53-year-old female with past medical history remarkable for breast cancer status-post lumpectomy and radiation on adjuvant anastrazole monotherapy presented to an outside hospital for progressive shortness of breath and weight loss... Diagnosis and management of CTEPH requires expert, multidisciplinary care, especially with the complexity of properly diagnosing the condition amidst other possible mimicking conditions.
- || anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Interaction between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early Stage Breast Cancer. (Pubmed Central) - Oct 13, 2021
LY75 and GPR160 participate in epithelial-to-mesenchymal transition and growth pathways, in both cases with SNP-dependent variation in regulation. Collectively, these studies identified SNPs that differentiate the efficacy of anastrozole and exemestane and they suggest additional genetic biomarkers for possible use in selecting an AI for a given patient.
- Ibrance (palbociclib) / Pfizer, camizestrant (AZD9833) / AstraZeneca, Verzenio (abemaciclib) / Eli Lilly
SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1 m who have not experienced disease progression on first-line therapy (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_362;
Acknowledgments: We thank Julia Mawer, PhD, of Oxford PharmaGenesis, UK, for medical writing assistance, which was funded by AstraZeneca. Funding: The SERENA-6 trial is funded and overseen by AstraZeneca.
- Ibrance (palbociclib) / Pfizer, camizestrant (AZD9833) / AstraZeneca
SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_361;
P3
In most countries, current standard-of-care first-line treatments include an aromatase inhibitor or fulvestrant, a selective ER degrader, combined with cyclin-dependent kinase 4/6 inhibitors...Patients with recurrent disease must have received adjuvant aromatase inhibitor or tamoxifen therapy for at least 24 months without relapse...Reused with permission. This abstract was accepted and previously presented at the 2021 ASCO Annual Meeting.
- giredestrant (GDC-9545) / Roche
Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_342;
P3
Giredestrant has been demonstrated to be more potent in vitro and achieves higher ER occupancy in vivo than fulvestrant, the only currently approved SERD...Pts are randomized 1:1 to oral 30 mg daily giredestrant or physician’s choice of standard ET (tamoxifen, anastrozole, letrozole, or exemestane, given according to prescribing information)...CONTACT INFORMATION For more information or to refer a patient, email global.rochegenentechtrials@roche.com or call 1-888-662-6728 (USA only). Clinicaltrials.gov number NCT04961996.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer (Hall 1) - Oct 9, 2021 - Abstract #SABCS2021SABCS_301;
P2
Conclusions To our knowledge this is the first and only ongoing study evaluating T-DXd with or without endocrine therapy for HR+, HER2-low breast cancer in the neoadjuvant setting. The study will shed light on clinical activity and biomarkers, which may guide larger confirmatory studies for patients with HR+, HER2-low early breast cancer.
- fulvestrant / Generic mfg.
Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106) (Hall 4A) - Oct 9, 2021 - Abstract #SABCS2021SABCS_224;
P3
(MJE) CPRIT RR140033, P50CA186784, P50-CA58223, U01 CA214125, U24CA210954, Gift from Ralph and Lisa Eads, McNair Scholarship. Trials.gov Identifier : NCT01953588.
- IO beyond TNBC (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_163;
P1, P2, P3
- tamoxifen / Generic mfg.
Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine (Hall 3) - Oct 9, 2021 - Abstract #SABCS2021SABCS_146;
Mutation of TP53 was strongly associated with Ki67 poor response. RNAseq profiling of patients treated with palbociclb as well as letrozole revealed high CCNE1 expression as associated with endocrine resistance.
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (clinicaltrials.gov) - Oct 7, 2021
P1, N=44, Not yet recruiting, Sponsor: Medical College of Wisconsin
RNAseq profiling of patients treated with palbociclb as well as letrozole revealed high CCNE1 expression as associated with endocrine resistance. Trial completion date: Jul 2025 --> Jan 2028 | Trial primary completion date: Jul 2024 --> Jan 2027
- | anastrozole / Generic mfg.
Trial completion, Trial completion date: IBIS II: Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer (clinicaltrials.gov) - Oct 6, 2021
P3, N=3864, Completed, Sponsor: Queen Mary University of London
Trial completion date: Jul 2025 --> Jan 2028 | Trial primary completion date: Jul 2024 --> Jan 2027 Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> May 2021
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion, Trial completion date: IBIS-II DCIS: Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (clinicaltrials.gov) - Oct 6, 2021
P3, N=2980, Completed, Sponsor: Queen Mary University of London
Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> May 2021 Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> May 2021
- | anastrozole / Generic mfg.
Journal: Anastrozole-Associated Lichenoid Eruption. (Pubmed Central) - Oct 1, 2021
Active, not recruiting --> Completed | Trial completion date: Jan 2022 --> May 2021 No abstract available
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - Sep 29, 2021
P3, N=463, Active, not recruiting, Sponsor: Eli Lilly and Company
No abstract available Trial completion date: Dec 2021 --> Feb 2023
- | anastrozole / Generic mfg.
Journal: Long-term effect of aromatase inhibition in aromatase excess syndrome. (Pubmed Central) - Sep 29, 2021
Spontaneous growth in AEXS varied, even in the same family. Our data suggest that early started, long-term inhibition by anastrozole promotes adult height in boys with AEXS.
- || dexamethasone / Generic mfg., abiraterone acetate / Generic mfg.
Clinical, Clinical data, Journal: Clinical outcomes in 21-hydroxylase deficiency. (Pubmed Central) - Sep 29, 2021
Negative consequencies are to large extent the result of the unphysiological glucocorticoid replacement. Modern management with improved follow-up and future addition of new drugs may improve outcomes.
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov) - Sep 27, 2021
P2, N=170, Recruiting, Sponsor: Priscilla McAuliffe
Modern management with improved follow-up and future addition of new drugs may improve outcomes. Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Oct 2021 --> Feb 2023
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) - Sep 24, 2021
P2, N=42, Recruiting, Sponsor: Emory University
Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Oct 2021 --> Feb 2023 Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Jun 2021 --> Aug 2022
- || anastrozole / Generic mfg.
Clinical, Journal: Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. (Pubmed Central) - Sep 24, 2021
These are the first results reporting BMD changes after stopping anastrozole in a breast cancer prevention setting. Our results show that the negative effects of anastrozole on BMD in the preventive setting are partially reversible.
- || anastrozole / Generic mfg.
Clinical, P2 data, Journal: Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). (Pubmed Central) - Sep 23, 2021
The 26.7% objective response rate with anastrozole is lower than reported in retrospective series, but the CBR was high and durable. The results underscore the importance of prospective trials in rare cancers.
- ||| tamoxifen / Generic mfg.
Clinical, P3 data, Journal: Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. (Pubmed Central) - Sep 22, 2021
Although third generation AIs put significantly more patients into 'clinical benefit', their tumours were not controlled for significantly longer. Overall, while this resulted in a significantly greater PFS in favour of the AIs, this did not translate into improvement in OS.
- | Soltamox (tamoxifen citrate) / Jazz
Trial completion date, Trial primary completion date: PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov) - Sep 22, 2021
P2, N=37, Active, not recruiting, Sponsor: Medical College of Wisconsin
Overall, while this resulted in a significantly greater PFS in favour of the AIs, this did not translate into improvement in OS. Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
- ||||| Ibrance (palbociclib) / Pfizer, anastrozole / Generic mfg., giredestrant (GDC-9545) / Roche
Clinical: 2/3 #ESMO21 #ADAPT TP👉PDL1 e CD8 associati a⬆️pCR in HER2+, #PIK3CA mut associate a⬇️outcome #coopERA👉#giredestrant in neoadj #HR+/HER2- ⬇️ki67 e⬆️CCCA vs anastrozole #Penelope-B👉QoL mantenuta con #palbociclib vs placebo in adj dopo non-PCR (Twitter) - Sep 21, 2021
- | NN1213 / Novo Nordisk
Trial primary completion date: GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) - Sep 21, 2021
P=N/A, N=90, Recruiting, Sponsor: University of Maryland, Baltimore
Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022 Trial primary completion date: Mar 2021 --> Mar 2022
- || anastrozole / Generic mfg.
@AnzolaDeToro hablando en @ForosSemana sobre la importancia de estar alertas a los factores de riesgos asociados a las enfermedades no transmisibles #Programadesaludjoven #younghealthprogramme @PlanUK @AstraZeneca @FundacionPlan (Twitter) - Sep 15, 2021
- | anastrozole / Generic mfg.
Journal: Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α. (Pubmed Central) - Sep 15, 2021
This matched case-control clinical study revealed that levels of estrone and estradiol above identified thresholds after six months of adjuvant anastrozole treatment were associated with increased risk of an EBCE. Preclinical laboratory studies revealed that anastrozole, but not exemestane or letrozole, is a ligand for estrogen receptor a. These findings represent potential steps towards individualized anastrozole therapy.
- ||| Ibrance (palbociclib) / Pfizer, anastrozole / Generic mfg., giredestrant (GDC-9545) / Roche
Clinical, P2 data: I'd like to add some more interesting papers to Paolo. immune gene-expression signatures vs. TILs in CALGB 40601 (C40601) and PAMELA trials. Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo. phase 2 coopERA BC study (Twitter) - Sep 8, 2021
- Abraxane (albumin-bound paclitaxel) / BMS, Otsuka, Tecentriq (atezolizumab) / Roche
Call the Gastroenterologist, It's Breast Cancer (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_849;
The patient then underwent chest wall radiation with subsequent hormone-based chemotherapy (Anastrozole & Letrozole), successfully achieving a state of remission...A novel treatment paradigm with the immunotherapy Atezolizumab, combined with nanoparticle albumin bound paclitaxel, is planned as her next step in management...Clinicians managing patients with lobular carcinoma should maintain a high level of suspicion when encountering mild abnormalities on imaging or patient reported gastrointestinal symptoms.Figure: Figure 1: Coronal CT image showing focal circumferential thickening of the ascending colon about 4.5 cm in length. Figure 2: Colonoscopy revealing benign appearing colonic polyps in the ascending colon (A) and hepatic flexure (B).
- Orencia (abatacept) / BMS, Humira (adalimumab) / Eisai, AbbVie
Atypical, Relapsing Type 1 Autoimmune Pancreatitis in a Patient with Breast Cancer and Rheumatoid Arthritis (Shoreline Exhibit Hall) - Sep 8, 2021 - Abstract #ACG2021ACG_782;
Given new pancreatic lesions, Adalimumab was discontinued and a trial of Abatacept was initiated. We are awaiting response to Abatacept before initiating RTX, given greater magnitude of immunosuppressive effects.
- || paclitaxel / Generic mfg., fulvestrant / Generic mfg.
Clinical, Review, Journal: Major clinical research advances in gynecologic cancer in 2019. (Pubmed Central) - Sep 4, 2021
Thereafter, we reviewed 5 topics, including systemic lymphadenectomy in the advanced stage with no gross residual tumor, secondary cytoreductive surgery in recurrent ovarian cancer according to the results of Gynecologic Oncology Group-213 trial, dose-dense weekly paclitaxel scheduling as first-line chemotherapy, the utility of intraperitoneal therapy in the advanced stage, and an update on poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer...For the field of radiation oncology, we discussed the utility of neoadjuvant chemotherapy added to chemoradiotherapy and the treatment of radiation-induced cystitis using hyperbaric oxygen. Finally, we discussed the use of individualized therapy with humanized monoclonal antibodies (trastuzumab emtansine and sacituzumab govitecan-hziy) and combination therapy (fulvestrant plus alpesilib, fulvestrant plus anastrozole, and ribociclib plus endocrine therapy) for women with advanced breast cancer.
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: RIGHT Choice: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Sep 2, 2021
P2, N=222, Recruiting, Sponsor: Novartis Pharmaceuticals
Finally, we discussed the use of individualized therapy with humanized monoclonal antibodies (trastuzumab emtansine and sacituzumab govitecan-hziy) and combination therapy (fulvestrant plus alpesilib, fulvestrant plus anastrozole, and ribociclib plus endocrine therapy) for women with advanced breast cancer. Trial primary completion date: Oct 2022 --> Mar 2022
- ||| Opdivo (nivolumab) / BMS
Trial termination: CheckMate 7A8: A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (clinicaltrials.gov) - Aug 31, 2021
P2, N=23, Terminated, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Oct 2022 --> Mar 2022 Active, not recruiting --> Terminated